Clinical trials: Respiratory Physiological Phenomena
Cystic Fibrosis
SD Cystic Fibrosis Study
Subject with Cystic Fibrosis have increased clearance of many drugs. Based on pre-clinical data SB656933 was found to have low clearance and high bio-availability.
- Trial name
- NCT00605761
- Testing
- SB656933
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
COVID-19 Pneumonia, Impaired Respiratory Function
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia…
- Trial name
- MAS-COVID (NCT04382651)
- Testing
- MAS825, Standard of Care (SoC)
- Where
- 21 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Asthma Attack
Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer
The investigators will study the use of a home-based spirometer (Spirobank Smart spirometer) that connects to a smartphone app (VitalFlo) in teenagers with persistent asthma to determine if clinically significant changes in lung…
- Conditions
- Asthma, Asthma Attack, Asthma, Allergic
- Trial name
- NCT03705325
- Testing
- Spirobank Smart spirometer
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- VitalFlo Inc.
Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
- Trial name
- CHINOOK (NCT03953300)
- Testing
- Benralizumab
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01521390
- Testing
- GSK573719 62.5 mcg (one strip), GSK573719 62.5 mcg(two strips), GSK573719 125 mcg (one strip)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
- Trial name
- FRONTIER-4 (NCT04631016)
- Testing
- Tozorakimab
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00379730
- Testing
- Prednisolone
- Where
- 5 sites in Argentina, Chile and 2 more
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Chronic Obstructive Pulmonary Disease
NVA237 Versus Placebo 12-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01709864
- Testing
- NVA237
- Where
- 54 sites in United States
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with…
- Trial name
- FAROS (NCT07525375)
- Testing
- GP MDI, BFF MDI
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
- Trial name
- LABD (NCT00791518)
- Testing
- No intervention
- Where
- 57 sites in United States
- Volunteers
- 1,084 people
- Sponsor
- GlaxoSmithKline
Respiratory Disease
Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies
The diagnosis of a lung function anomaly requires the evaluation of pulmonary function by spirometry. However, some patients (e.g.
- Trial name
- NCT04006964
- Testing
- Resmon PRO FULL v2
- Where
- 6 sites in United States, Italy
- Volunteers
- 579 people
- Sponsor
- Restech Srl
Asthma
A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms.
- Trial name
- MONA (NCT00686335)
- Testing
- Lodotra, Cortancyl
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Amgen
Asthma
Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to…
- Trial name
- NCT01348139
- Testing
- AZD3199
- Where
- 3 sites in Sweden
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Respiratory Physiology Under High Flow Therapy
The aim of this study is to gain knowledge about effects of high flow transnasal insufflation on various breathing parameters like intratracheal pressure conditions, CO2 elimination, breathing frequency and tidal volume.
- Trial name
- NCT01509703
- Testing
- High flow therapy
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
- Trial name
- NCT02802345
- Testing
- Nintedanib, Sildenafil
- Where
- 85 sites in United States, Australia and 11 more
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients…
- Trial name
- NCT00144339
- Testing
- tiotropium
- Where
- 490 sites in United States, Argentina and 35 more
- Volunteers
- 5,993 people
- Sponsor
- Boehringer Ingelheim
Lung Ultrasound, Respiratory Distress Syndrome, Newborn
Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With Surfactant
The ULISSES study looks at how doctors use bedside ultrasound to help treat premature babies with breathing problems caused by Respiratory Distress Syndrome (RDS).
- Trial name
- ULISSES (NCT07070167)
- Testing
- Intratracheal administration of surfactant
- Where
- 2 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Chiesi Poland Sp. z o.o.